首頁 > 市場調查報告書 > 製藥

開發平台分析

升糖素市場規模、佔有率和成長分析（按適應症、給藥途徑、劑型、最終用戶和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1913953

升糖素市場規模、佔有率和成長分析（按適應症、給藥途徑、劑型、最終用戶和地區分類）－2026-2033年產業預測

Glucagon Market Size, Share, and Growth Analysis, By Indication (Hypoglycemia, Diabetic Ketoacidosis), By Route of Administration (Intravenous, Subcutaneous), By Formulation, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月30日 | 出版商:

SkyQuest | 英文 185 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球升糖素市場規模為 6.4448 億美元，預計將從 2025 年的 6.8315 億美元成長到 2033 年的 10.8884 億美元，預計在預測期（2026-2033 年）內將以 6% 的複合年成長率。

全球升糖素市場正經歷顯著成長，這主要得益於糖尿病盛行率的上升以及對有效控制嚴重低血糖需求的日益成長。急救注射裝置的普及和鼻用升糖素製劑的進步提高了患者的用藥便利性和治療效果，從而推動了這一成長。此外，加強對醫護人員和病患關於如何快速應對低血糖發作的教育也進一步刺激了市場需求。藥物輸送系統的持續創新和政府的醫療保健支援措施也促進了市場擴張。然而，高昂的治療成本、醫療資源匱乏地區對胰高血糖素的認知度低、對副作用的擔憂、嚴格的監管要求以及對低溫運輸物流的依賴等挑戰，仍然是市場滲透和規模化發展的主要障礙。

全球升糖素市場促進因素

全球糖尿病（尤其是第1型糖尿病）盛行率的不斷上升是升糖素市場擴張的主要驅動力。胰島素依賴型患者時時刻刻面臨嚴重低血糖的風險，需要及時介入。這種迫切的醫療需求推動了包括醫院、診所和居家醫療在內的各種醫療機構對升糖素治療的需求。隨著人們對有效升糖素應對低血糖發作重要性的認知不斷提高，為了確保患者安全和有效管理糖尿病相關緊急情況，市場持續顯著成長。

限制全球升糖素市場的因素

創新型升糖素給藥系統，例如預填充自動注射器和鼻腔粉末，研發和生產成本高昂，這可能成為其廣泛應用的障礙。這種經濟負擔在低收入和中等收入國家尤為突出，高昂的價格會阻礙患者獲得這些藥物。此外，不斷上漲的成本也會影響醫療保健系統和保險公司，阻礙這些先進治療方法的廣泛應用和普及。這些經濟限制對全球升糖素市場的整體成長和有效性構成挑戰，限制了不同族群患者療效改善的潛力。

全球升糖素市場趨勢

受藥物傳遞系統技術的顯著進步推動，全球升糖素市場正處於強勁成長期。穩定的液體製劑、鼻噴霧和自動注射器等創新技術正在革新升糖素的給藥方式，提高緊急應變能力和患者依從性。這些進步無需藥物復溶，提高了儲存穩定性，並實現了便捷給藥，使患者在低血糖發作時更容易獲得治療。隨著人們越來越關注易用性和可靠性強的方便用戶使用型解決方案，醫療服務提供者和患者對這些先進給藥方式的接受度不斷提高，預計市場將繼續擴張。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Sun Pharmaceuticals Industries
Zealand Pharma
Biocon
KemPharm
Baxter International
Sandoz
Teva Pharmaceuticals Industries
Reddy's Laboratories
Mylan
Pfizer
Novo Nordisk
Xeris Pharmaceuticals
Eli Lilly and Company

結論與建議

簡介目錄

Product Code: SQMIG35H2367

Global Glucagon Market size was valued at USD 644.48 Million in 2024 and is poised to grow from USD 683.15 Million in 2025 to USD 1088.84 Million by 2033, growing at a CAGR of 6% during the forecast period (2026-2033).

The global glucagon market is experiencing significant growth, driven by the increasing prevalence of diabetes and the rising need for effective management of severe hypoglycemia. This growth is fueled by the widespread adoption of emergency injectable devices and advancements in nasal glucagon formulations, which enhance patient accessibility and outcomes. Efforts to educate healthcare professionals and patients about prompt responses to hypoglycemic episodes are further amplifying market demand. Additionally, continuous innovations in drug delivery systems and supportive government healthcare initiatives contribute to the market's expansion. However, challenges such as high treatment costs, limited awareness in underserved regions, apprehensions regarding side effects, and stringent regulatory requirements, alongside dependence on cold-chain logistics, present substantial barriers to market penetration and scalability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glucagon market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glucagon Market Segments Analysis

Global Glucagon Market is segmented by Indication, Route of Administration, Formulation, End-User and region. Based on Indication, the market is segmented into Hypoglycemia, Diabetic Ketoacidosis and Metabolic Disease Trials. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Intramuscular. Based on Formulation, the market is segmented into Injectable Kits, Liquid Stable Autoinjectors, Nasal Powder and Liquid Stable Vials. Based on End-User, the market is segmented into Hospitals, Clinic, Drug Stores, Online Pharmacies and Home Care Setting. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glucagon Market

The rising prevalence of diabetes, particularly type 1 diabetes, worldwide significantly propels the expansion of the glucagon market. Individuals reliant on insulin are at constant risk of severe hypoglycemia, necessitating prompt intervention. This urgent healthcare requirement heightens the demand for glucagon treatments in various settings, including hospitals, clinics, and homecare environments. As awareness grows regarding the critical need for effective glucagon responses to hypoglycemic episodes, the market continues to experience substantial growth, driven by the necessity to ensure patient safety and effective management of diabetes-related emergencies.

Restraints in the Global Glucagon Market

The development and production of innovative glucagon delivery systems, like prefilled autoinjectors and nasal powders, entails significant costs, which can be a barrier to their widespread adoption. This financial burden is particularly pronounced in low- and middle-income countries, where high prices may deter their utilization. Moreover, the escalation in costs impacts healthcare systems and insurance providers, consequently hindering the broader distribution and accessibility of these advanced treatment options. Such economic constraints pose a challenge to the overall growth and efficacy of the global glucagon market, limiting its potential to improve patient outcomes across diverse demographics.

Market Trends of the Global Glucagon Market

The Global Glucagon market is witnessing a robust growth trajectory, driven by significant technological advancements in drug delivery systems. Innovations such as liquid-stable formulations, nasal sprays, and autoinjectors are revolutionizing how glucagon is administered, enhancing emergency response and patient compliance. These advancements eliminate the necessity for reconstitution, improve shelf stability, and facilitate straightforward administration, making it more accessible for patients during hypoglycemic episodes. With an increasing focus on user-friendly solutions that prioritize ease of use and reliability, the market is set for continued expansion as healthcare providers and patients alike embrace these cutting-edge delivery methods.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Glucagon Market Size by Indication & CAGR (2026-2033)

Market Overview
Hypoglycemia
Diabetic Ketoacidosis
Metabolic Disease Trials

Global Glucagon Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intravenous
Subcutaneous
Intramuscular

Global Glucagon Market Size by Formulation & CAGR (2026-2033)

Market Overview
Injectable Kits
Liquid Stable Autoinjectors
Nasal Powder
Liquid Stable Vials

Global Glucagon Market Size by End-User & CAGR (2026-2033)

Market Overview
Hospitals
Clinic
Drug Stores
Online Pharmacies
Home Care Setting

Global Glucagon Market Size & CAGR (2026-2033)

North America (Indication, Route of Administration, Formulation, End-User)
- US
- Canada
Europe (Indication, Route of Administration, Formulation, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Indication, Route of Administration, Formulation, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Indication, Route of Administration, Formulation, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Indication, Route of Administration, Formulation, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Sun Pharmaceuticals Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zealand Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KemPharm
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xeris Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments